FDA Approves Rasonque, First Broad RAS-Targeted Therapy, for Pancreatic Cancer
FDA approved Revolution Medicines’ once-daily oral Rasonque (daraxonrasib) for adults with metastatic pancreatic adenocarcinoma who received at least one prior systemic therapy or are not candidates for multiagent systemic therapy. In the 500-patient randomized…
